Natera Facing Class Action Lawsuit Over Allegedly Misleading IVF Genetic Testing Claims

A major genetic testing company is facing legal trouble after a proposed class action lawsuit accused it of aggressively marketing a costly in vitro fertilization (IVF) screening tool as highly accurate and beneficial despite decades of contradictory medical science. The lawsuit, filed on June 2, 2026, in California federal court, claims that Natera, Inc. deliberately suppressed critical information about the true effectiveness of its Spectrum preimplantation genetic testing for aneuploidy (PGT-A) to profit off hopeful, vulnerable families. Everyday people undergoing the exhausting and expensive IVF process were allegedly misled into paying thousands of dollars out of pocket for an unproven add-on procedure that may not improve their chances of having a child.

Understanding the PGT-A Genetic Testing Lawsuit Against Natera

The legal action centers around Natera’s optional Spectrum PGT-A screening, an embryo selection tool heavily marketed to patients navigating the emotional journey of IVF. The procedure involves extracting a small sample of cells from an embryo’s trophectoderm the layer of tissue that eventually forms the placenta—and testing those cells for chromosomal abnormalities before implantation occurs. According to the complaint, Natera aggressively promoted this test to consumers by claiming it boasted an accuracy rate of greater than 99 percent. Marketing materials allegedly promised that utilizing the Spectrum test would drastically increase embryo implantation rates, boost overall live birth rates, and lower the risk of devastating miscarriages.

However, the 68-page lawsuit claims these bold marketing assertions were built on deception rather than sound medicine. Plaintiffs allege that Natera intentionally hid the reality that scientific consensus does not back up its claims of high efficacy. Instead of providing peace of mind, the lawsuit argues that the screening can give misleading results that do not accurately represent the health of the entire embryo, ultimately leading families to make critical fertility decisions based on deeply flawed data.

The Scientific Reality Discovered Behind False Marketing Claims

While Natera allegedly sold its Spectrum testing as a definitive answer to successful pregnancies, medical research tells a different story. The lawsuit points to a vast archive of scientific literature spanning several decades that fundamentally challenges the clinical benefits of PGT-A screenings. A major issue highlighted in the complaint is that a small cell sample taken from the outermost layer of an embryo may fail to reliably reflect the genetic makeup of the embryo as a whole. Scientists have found that developing embryos often naturally possess a mosaic mixture of both healthy and abnormal cells, and many embryos have the remarkable ability to self-correct chromosomal abnormalities over time.

Because of this, embryos labeled as “abnormal” by Natera’s testing could actually go on to become completely healthy babies. The lawsuit points out that multiple independent studies show absolutely no statistical difference in clinical pregnancy, miscarriage, or live-birth rates between standard IVF cycles and IVF cycles that incorporate PGT-A. The true accuracy rating for the procedure is allegedly significantly lower than Natera ever disclosed to the public, meaning families may have discarded completely viable embryos based on false test results.

Decades of Research Challenge Natera’s Bold Scientific Assertions

The complaint systematically breaks down how major medical associations and peer-reviewed journals have long warned against the routine use of PGT-A testing. Specifically, the lawsuit cites a landmark 2011 meta-analysis of randomized clinical trials that uncovered zero evidence that preimplantation genetic screenings improved live birth rates when compared to conventional IVF treatments. Furthermore, a 2021 study published in the prestigious New England Journal of Medicine concluded that standard, conventional IVF actually yielded a higher cumulative live-birth rate than IVF cycles paired with PGT-A testing for patients who already had a good prognosis.

Leading healthcare organizations have similarly expressed skepticism about the widespread commercialization of these tests. The lawsuit notes that both the American Society for Reproductive Medicine and the American College of Obstetricians and Gynecologists have issued guidance stating that there is currently insufficient evidence to support the routine use of PGT-A for patients. Despite these widespread institutional warnings, Natera allegedly continued to market the expensive screening heavily to individuals facing advanced maternal age or history of recurrent pregnancy complications—demographics desperately looking for solutions.

High Financial and Emotional Tolls Imposed on IVF Patients

Navigating infertility is one of the most stressful and financially draining experiences a person can face, and the lawsuit argues that Natera took unfair advantage of families in these positions. The Spectrum PGT-A testing came with an incredibly steep price tag, costing consumers roughly $5,000 per IVF cycle. Because medical groups do not consider the testing routine or scientifically proven to be effective, health insurance companies rarely provide coverage for the procedure. As a result, everyday people were forced to pay thousands of dollars entirely out of pocket, often sinking into further medical debt based on false promises of a healthy baby.

The emotional toll is equally severe. By alleging that Natera’s marketing was deceptive, the lawsuit brings to light the reality that patients may have experienced unnecessary grief, thinking their embryos were entirely unviable when they were not. Though Natera officially discontinued its Spectrum PGT-A testing product in December 2025, the lawsuit seeks to hold companies accountable for the years of alleged deception that preceded the product’s quiet retirement from the fertility market.

Consumer Protection Laws Invoked to Hold Natera Accountable

To protect everyday people who fell victim to these alleged misrepresentations, the lawsuit invokes a series of robust state consumer protection statutes. Specifically, the legal complaint charges Natera with violating the Illinois Consumer Fraud and Deceptive Business Practices Act, along with the New York General Business Law and New York Consumer Protection Law. These strict laws are designed to prevent large corporations from utilizing false advertising, omitting material health facts, and engaging in deceptive business conduct to boost their corporate bottom line at the expense of ordinary citizens.

The plaintiffs argue that if Natera had been transparent about the limitations of PGT-A, the lack of randomized clinical trials supporting its claims, and the fact that its own 2018 study had severe limitations, consumers would never have agreed to purchase the test. The lawsuit seeks to represent a nationwide class of consumers to recover the money spent on these expensive, allegedly unproven tests.

See If You May Be Eligible for the Natera Class Action

When a company faces a class action lawsuit, it is important to know that you don’t stand alone against powerful corporate legal teams. This proposed class action lawsuit aims to seek justice and financial recovery for a wide group of affected individuals.

You may be eligible to benefit from this legal action if you fall into the following category:

• You are an individual living in the United States who purchased Spectrum PGT-A genetic testing from Natera, Inc. during an IVF cycle.

Currently, there is no active filing deadline or official claims form to submit, as the lawsuit has just been filed in federal court and must work its way through the legal system before any settlement can be reached.